Status:
COMPLETED
Efficacy Study to Evaluate the Effect of Nitric Oxide on the Treatment of Tinea Pedis (Athlete's Foot)
Lead Sponsor:
Nitric BioTherapeutics, Inc
Conditions:
Tinea
Eligibility:
All Genders
19+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the fungicidal efficacy of nitric oxide and it's effect on the clinical signs and symptoms associated with Tinea Pedis
Eligibility Criteria
Inclusion
- Positive clinical findings for moccasin, interdigital or bullous tinea pedis as determined by direct clinical examination
- Must have a clinical symptom severity score of at least 20 on a possible 64 point scale
- Written informed consent must be obtained from the subject.
- Must ≥ 19 years of age
- Must agree to avoid professional pedicures or application of any nail polish product or nail cosmetic to the toenails after the screening visit until the conclusion of the trial.
- Must agree to take measures to avoid pregnancy during the 12 day (or 26 day if in cross over group) study period
Exclusion
- Has a diagnosis of either psoriasis or eczema
- Has a visual diagnosis, by the investigator, of onychomycosis.
- Use of topical antifungals e.g. (clotrimazole, ketoconazole,miconazole, oxiconazole- (Oxistat®, Glaxo Smith Kline), sulconazole, naftifine (Naftin®, Merz), terconazole, econazole nitrate (Spectazole®, Ortho-McNeil), butoconazole ,Fluconazole, ciclopirox olamine-(Loprox®, Medicis), tolnaftate, haloprogin), Zeasorb-AF , antibacterials and corticosteroids in the preceding 5 days of screening visit (Day 1)
- Use of systemic corticosteroids in the preceding 7 days of screening visit (Day 1)
- Use of systemic antifungals in the preceding 7 days of screening visit (Day1) including - (terbinafine - (Lamisil®, Novartis), Itraconazole - (Sporanox®, Janssen), fluconazole- (Diflucan®, Pfizer), ketoconazole, miconazole, griseofulvin (Gris-PEG®, Pedinol), butoconazole, terconazole, Potassium iodide)
- Has used any investigational drug(s) within 30 days preceding screening visit (Day 1)
- Has cardiovascular disease, diabetes mellitus, Cushing's Disease, hematological malignancy, chronic mucocutaneous candidiasis or atopy
- Is pregnant or is a nursing mother
- Is a woman of child bearing potential who is not using an adequate form of contraception (or abstinence)
- Is \< 19 years of age
- Suffers from a condition, which, in the opinion of the medical investigator, would compromise his/her safety
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2009
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00771342
Start Date
December 1 2008
End Date
August 1 2009
Last Update
February 3 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vancouver General Hospital
Vancouver, British Columbia, Canada, V5Z 1M9